![]() |
![]() |
J Yeungnam Med Sci > Volume 39(4); 2022 > Article |
|
Diagnostic criteria |
---|
Migraine without aura |
A. At least five attacks fulfilling criteria B–D |
B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)a) |
C. Headache has at least two of the following four characteristics: unilateral location, b)pulsating quality, moderate or severe pain intensity, aggravation by or causing avoidance of routine physical activity |
D. During headache, at least one of the following: nausea and/or vomiting, photophobia and phonophobia |
E. Not better accounted for by another ICHD-III diagnosis |
Migraine with aura |
A. At least two attacks fulfilling criteria B and C |
B. One or more of the following fully reversible six aura symptoms: visual, sensory, speech and/or language, motor, brainstem, retinal |
C. At least two of the following four characteristics: |
1. At least one aura symptom spreads gradually over 5 minutes, and/or two or more symptoms occur in succession |
2. Each individual aura symptom lasts 5–60 minutes |
3. At least one aura symptom is unilateral |
4. The aura is accompanied, or followed within 60 minutes, by headache |
D. Not better accounted for by another ICHD-III diagnosis, and TIA has been excluded |
ICHD-III beta, International Classification of Headache Disorders, 3rd edition beta version; TIA, transient ischemic attack.
Reprinted from Lee [3] according to the Creative Commons License.
Reprinted from Lee [3] according to the Creative Commons License.
Adapted from Manoyana et al. [24] according to the Creative Commons License.
Drug | Usual dosage | Maximum per day |
---|---|---|
Acetaminophen (syrup/tablet) | 10–12.5 mg/kg every 4–6 hr | 75 mg/kg |
Age >13 yr: 650 mg every 6 hr | 4,000 mg | |
Ibuprofen (syrup/tablet) | 10 mg/kg every 6–8 hr | 30 mg/kg |
Age >12 yr: 200–600 mg every 6 hr | 2,400 mg | |
Naproxen sodium (tablet) | 5–7 mg/kg every 8–12 hr | |
Age >13 yr: 250 mg every 8 hr | 1,250 mg | |
Diclofenac (tablet/injection) | Per oral: 0.3–1 mg/kg every 8 hr | 150 mg |
IV, IM: 0.3–1 mg/kg every 12 hr | 150 mg | |
Ketorolaca) (injection) | IV: 0.5 mg/kg | 15 mg |
Age >15 yr: 10 mg | 60 mg | |
Prochlorperazine (tablet) | Age >5 yr: 0.25 mg/kg every 8 hr | 10 mg |
Age >12 yr: 5–10 mg every 8 hr | 30 mg | |
Domperidone (solution/tablet) | Age >12 yr: 0.25 mg/kg every 8 hr | 30 mg |
10 mg every 8 hr | ||
Almotriptan (tablet) | Age >12 yr: 6.25–12.5 mg | 25 mg |
Sumatriptan/naproxen (tablet) | Age >12 yr: 10 mg/60 mg | 85 mg/500 mg |
Adapted from Im and Cho [38] according to the Creative Commons License.
Advances in management of pediatric chronic immune thrombocytopenia: a narrative review ;0()
Hypertension and cognitive dysfunction: a narrative review ;0()
Long-term management of Graves disease: a narrative review2023 January;40(1)
Pain in amyotrophic lateral sclerosis: a narrative review2022 July;39(3)
Beneficial effects of intermittent fasting: a narrative review2023 January;40(1)
![]() |
![]() |